SEC Form 4 · accession 0000899243-17-020280
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey S Farrow
Officer — Chief Financial Officer
Period of report
Aug 11, 2017
Accepted (ET)
Aug 14, 2017 · 9:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Aug 11, 2017 | A | 15,000 | A | — | — | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
- F2The RSUs vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.